In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
  • Year

    Select Year(s)

  • Session Type

    Select Session Type(s)

  • Resource type

    Select Resource type(s)

  • Topic

    Select Topic(s)

Filters (0)
  • sub-topic
  • Year
  • Session Type
  • Resource type
  • Topic
  • sub-topic
  • Year
  • Session Type
  • Resource type
  • Topic

Sponsored content

Presentations below are part of sessions sponsored by Novartis Pharma AG

66 results for your search

2018

Advancing standard of care in post-myocardial infarction (MI) patients with elevated high sensitivity C-reactive protein (hsCRP).

Congress : EuroPrevent 2018

  • Session : Inflammation in atherosclerosis: translating science into practicable solutions.
  • Speaker : U Landmesser (Berlin,DE), P Libby (Boston,US), W Koenig (Munich,DE)
  • Sponsored by Novartis Pharma AG

Some member-only content

2018

Clinical residual cardiovascular risk: what are the markers?

Congress : EuroPrevent 2018

  • Session : Inflammation in atherosclerosis: translating science into practicable solutions.
  • Speaker : W Koenig (Munich,DE)
  • Sponsored by Novartis Pharma AG

Some member-only content

2018

Inflammation in atherosclerosis: translating science into practicable solutions.

Congress : EuroPrevent 2018

  • Session : Inflammation in atherosclerosis: translating science into practicable solutions.
  • Speaker : P Libby (Boston,US)
  • Sponsored by Novartis Pharma AG

Some member-only content

2018

Summary and closure - Inflammation in atherosclerosis: translating science into practicable solutions.

Congress : EuroPrevent 2018

  • Session : Inflammation in atherosclerosis: translating science into practicable solutions.
  • Speaker : U Landmesser (Berlin,DE)
  • Sponsored by Novartis Pharma AG

Some member-only content

2018

Welcome and introduction - Inflammation in atherosclerosis: translating science into practicable solutions.

Congress : EuroPrevent 2018

  • Session : Inflammation in atherosclerosis: translating science into practicable solutions.
  • Speaker : U Landmesser (Berlin,DE)
  • Sponsored by Novartis Pharma AG

Some member-only content

2017

Achieving contemporary treatment goals in patients with HFrEF - a practical case study.

Congress : ESC Congress 2017

  • Session : Evolving clinical practice for optimized treatment of patients with heart failure with reduced ejection fraction (HFrEF)
  • Speaker : R Wachter (Leipzig,DE)
  • Sponsored by Novartis Pharma AG

Some member-only content

2017

Advancing standard of care in patients with HFrEF - what does it take?

Congress : ESC Congress 2017

  • Session : Evolving clinical practice for optimized treatment of patients with heart failure with reduced ejection fraction (HFrEF)
  • Speaker : A Pathak (Toulouse,FR), R Wachter (Leipzig,DE), M G Crespo-Leiro (La Coruna,ES), A P Maggioni (Milano,IT), R S Gardner (Linithgow,GB)
  • Sponsored by Novartis Pharma AG

Some member-only content

2017

Atherosclerosis and the cardiovascular continuum.

Congress : ESC Congress 2017

  • Session : Atherosclerosis and secondary cardiovascular disease prevention: inflammation and low density lipoprotein (LDL)-cholesterol
  • Speaker : P Libby (Boston,US)
  • Sponsored by Novartis Pharma AG

Some member-only content

2017

Audience Q&A - Atherosclerosis, cardiovascular risk factors and secondary prevention: are we making progress?

Congress : ESC Congress 2017

  • Session : Atherosclerosis, cardiovascular risk factors and secondary prevention: are we making progress?
  • Speaker : W Koenig (Munich,DE), P M Ridker (Boston,US), T F Luscher (London,GB), P Libby (Boston,US)
  • Sponsored by Novartis Pharma AG

Some member-only content

2017

Audience Q&A and panel discussion - Atherosclerosis and secondary cardiovascular disease prevention: inflammation and LDL-cholesterol.

Congress : ESC Congress 2017

  • Session : Atherosclerosis and secondary cardiovascular disease prevention: inflammation and low density lipoprotein (LDL)-cholesterol
  • Speaker : P Libby (Boston,US)
  • Sponsored by Novartis Pharma AG

Some member-only content

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are